Treats superficial infections of the external auditory canal caused by organisms…. NDA 12179, held by Hikma. Acetic Acid, Glacial.
As of Nov 13, 2026, NDA 12179 (Vosol), held by Hikma, was first approved by FDA on May 17, 1960, with 11 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 17, 1960 | Original applicationNew combination · Standard review | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Vosol2% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · solution/drops;otic | Acetic Acid, Glacial | DiscontinuedReference drug |
| Oct 16, 1997 | Supplement 19Manufacturing · Standard review | Approved | None posted |
| Jul 29, 1997 | Supplement 18Labeling · Standard review | Approved | None posted |
| Dec 21, 1995 | Supplement 16Manufacturing · Standard review | Approved | None posted |
| Jun 29, 1988 | Supplement 15Labeling | Approved | None posted |
| Aug 3, 1987 | Supplement 12Labeling | Approved | None posted |
| Aug 26, 1986 | Supplement 14Manufacturing · Standard review | Approved | None posted |
| Jun 24, 1985 | Supplement 13Manufacturing · Standard review | Approved | None posted |
| Jun 6, 1984 | Supplement 11Manufacturing · Standard review | Approved | None posted |
| Jun 6, 1984 | Supplement 8Labeling | Approved | None posted |
| Jun 2, 1975 | Supplement 6Manufacturing · Standard review | Approved | None posted |
| Jul 16, 1974 | Supplement 5 | Approved | None posted |
| May 17, 1960 | Original applicationNew combination · Standard review | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters